AstraZeneca: A Science-Driven, Innovative, and Research-Oriented Pharmaceutical Company Contributing to Global Health Challenges
We have been operating in Turkey since 1999 with over 500 employees, aiming to transform healthcare, improve patients’ lives, and develop solutions to the world’s most significant health challenges.
With a healthcare market value of $45.8 billion, AstraZeneca is one of the world’s leading innovative and research-oriented pharmaceutical companies. Operating in more than 125 countries and manufacturing in 16 locations, AstraZeneca invests an average of $10.9 billion annually in R&D. We focus on key therapeutic areas, including Cardiovascular, Renal, and Metabolic Diseases, Oncology, Vaccines and Immune Therapies, and Respiratory and Immunology, striving for global scientific leadership in these fields.
AstraZeneca’s Impact on Turkey in Its 25th Year
Twenty-five years ago, two well-established pharmaceutical companies, Astra and Zeneca, merged under the AstraZeneca umbrella, bringing together a science-driven, innovative, and people-centered vision.
To mark AstraZeneca’s 25th anniversary, AstraZeneca Turkey commissioned EY Turkey to prepare the AstraZeneca’s Impact on Turkey Report based on data provided by the company. The report sheds light on AstraZeneca’s economic impact throughout the supply chain and its contribution to employment across various sectors in our country. It also highlights the importance of collaborations that direct scientific knowledge toward the advancement of public health.
